Bivigam market forecast points to faster growth on rising immune disorder demand

The global Bivigam market is expected to expand as immune disorder diagnoses rise, healthcare spending grows and personalized medicine gains ground. North America held the largest market share in 2025, while Asia-Pacific is projected to grow fastest through the forecast period.

Why it matters: - Bivigam is part of the growing IVIG market used to treat primary humoral immunodeficiency, a condition that leaves patients unable to produce enough antibodies. - Rising immune disorder cases and broader use of immunoglobulin therapies are pushing demand for specialized treatments. - The market outlook matters for hospitals, infusion providers, plasma supply chains and patients who depend on long-term immune support.

What happened: - The Bivigam market is gaining momentum as advances in medical treatment and higher awareness of immune-related disorders increase demand. - The market is being shaped by more patients needing specialized therapies and by expectations for continued expansion through 2026. - The full market report is available from The Business Research Company. - A free sample of the report is also offered.

The details: - Bivigam is an IVIG therapy designed to treat primary humoral immunodeficiency, a group of disorders in which the immune system does not produce enough antibodies to fight infections effectively. - Bivigam is derived from human plasma and provides antibodies that help support immune function in patients with primary humoral immunodeficiency. - Historical market growth has been driven by clinical effectiveness of IVIG therapies, increased awareness of immunodeficiency disorders, hospital-based infusion protocols, growth in plasma donation networks and regulatory approvals for IVIG uses. - Future growth is expected to come from more immune disorder diagnoses, broader IVIG use in neurological conditions, growth in home infusion services, better plasma supply chains and an aging population. - Forecast trends include wider IVIG adoption, more diagnoses of primary immunodeficiency, expanded uses beyond primary immunodeficiency, improved plasma collection and fractionation techniques and higher demand for long-term immune support. - One cited example of growing need came in October 2024, when the UK Health Security Agency reported 6,008 HIV diagnoses in England in 2023, up 51% from 3,975 in 2022. - Healthcare spending is also rising. In May 2024, the UK Office for National Statistics reported a 5.6% nominal increase in total healthcare expenditure for 2023, 0.9% higher than in 2022. - Personalized medicine is another support for market growth. In February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - Of those approvals, seven were cancer drugs and three were treatments for other conditions.

Between the lines: - The market story is less about a single drug and more about a wider shift toward immune-support therapies that can be used across more patient groups. - The report ties Bivigam demand to structural drivers such as aging populations, stronger diagnostics and more advanced infusion delivery, which suggests steady rather than speculative growth. - North America held the largest share of the Bivigam market in 2025, while Asia-Pacific is projected to grow the fastest during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa.

What's next: - The market is expected to keep expanding as immune disorder prevalence rises and IVIG applications broaden. - Growth in home infusion services and plasma supply improvements could make treatment access easier and support wider adoption. - The Business Research Company says its 2026 market reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and technology and future trend analysis.

The bottom line: - Bivigam is positioned to benefit from a bigger global push for immunoglobulin therapies, with demand underpinned by more diagnoses, higher healthcare spending and broader personalized treatment use.